Cognitive impairment in multiple sclerosis: An exploratory analysis of environmental and lifestyle risk factors by Amato, M. P. et al.
RESEARCH ARTICLE
Cognitive impairment in multiple sclerosis: An
exploratory analysis of environmental and
lifestyle risk factors
Maria Pia AmatoID
1,2*, Elio Prestipino1, Angelo BellinviaID1, Claudia Niccolai1,
Lorenzo Razzolini1, Luisa Pastò3, Roberto Fratangelo1, Laura Tudisco1,
Mattia Fonderico1, Paolo Luca Mattiolo1, Benedetta Goretti1, Giovanni Bosco Zimatore4,
Nunzia Alessandra Losignore4, Emilio Portaccio5, Francesco Lolli1
1 Department NEUROFARBA, Section of Neurosciences, University of Florence, Florence, Italy, 2 IRCCS
Fondazione Don Carlo Gnocchi, Florence, Italy, 3 SOD Neurological Rehabilitation, Careggi University
Hospital, Florence, Italy, 4 Operative Unit of Neurology, Dimiccoli General Hospital, Barletta, Italy, 5 SOC




Many potentially modifiable risk factors for MS are investigated. It is not known, however, if
these factors also apply to MS-related cognitive impairment (CI), a frequent consequence of
MS.
Objective
The aim of our study was to assess risk factors for CI in MS patients, focusing on environ-
mental exposures, lifestyle and comorbidities.
Methods
We included MS patients referring to MS Centers in Florence and Barletta between 2014
and 2017. Neuropsychological performance was assessed through the Rao’s battery and
Stroop test, cognitive reserve (premorbid intelligence quotient–IQ) was evaluated using the
National Adult Reading Test (NART). Potential risk factors were investigated through a
semi-structured questionnaire.
Results
150 patients were included. CI was detected in 45 (30%) subjects and was associated with
older age (p<0.005), older age at MS onset (p = 0.016), higher EDSS score (p<0.005), pro-
gressive disease course (p = 0.048) and lower premorbid IQ score (p<0.005). As for risk fac-
tors, CI was related with lower physical activity in childhood-adolescence (p<0.005). In
women, hormonal therapy resulted to be protective against CI (p = 0.041). However, in the
multivariable analysis, the only significant predictors of CI were older age (p<0.05; OR 1.06,
95% CI 1.02–1.10) and lower premorbid IQ (p<0.05; OR 0.93, 95% CI: 0.88–0.98).







Citation: Amato MP, Prestipino E, Bellinvia A,
Niccolai C, Razzolini L, Pastò L, et al. (2019)
Cognitive impairment in multiple sclerosis: An
exploratory analysis of environmental and lifestyle
risk factors. PLoS ONE 14(10): e0222929. https://
doi.org/10.1371/journal.pone.0222929
Editor: Orhan Aktas, Heinrich-Heine-Universitat
Dusseldorf, GERMANY
Received: March 12, 2019
Accepted: September 10, 2019
Published: October 21, 2019
Copyright: © 2019 Amato et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
Removing IQ from the model, CI was associated with higher EDSS (p = 0.030; OR 1.25,
95% CI 1.02–1.53) and, marginally, previous physical activity (p = 0.066; OR 0.49, 95% CI:
0.23–1.05)
Conclusions
Our findings suggest that physical activity in childhood-adolescence could be a contributor
to cognitive reserve building, thus representing a potential protective factors for MS-related
CI susceptible to preventive strategies.
Introduction
Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative demyelinating disease
of the central nervous system (CNS) with onset usually in young adulthood with a female to
male ratio of nearly three to one, especially in relapsing-remitting MS (RRMS) patients [1].
While the pathogenesis of the disease is most likely autoimmune, the etiology is multifacto-
rial: multiple factors, both genetic and environmental, determine disease risk and interact with
one another in a complex manner. Beyond genetic susceptibility, many environmental, poten-
tially modifiable factors have been identified to play a role in of the development MS, and, in a
few cases, also in the prognosis of the disease. The most widely investigated include Epstein-
Barr virus (EBV) infection, smoking, low levels of vitamin D, obesity and comorbidities [2].
Cognitive impairment (CI) is a common feature of MS, affecting approximately 40% to
70% of patients at any time in their disease course [3]. The neuropsychological pattern is usu-
ally characterized by deficits in information processing speed and complex attention, episodic
memory, executive functions and visuospatial abilities. Regardless of the disease duration and
level of physical disability, CI has a significant functional impact and negatively affects various
aspects of the patients’ quality of life and lifestyle. Compared with cognitively preserved
patients, patients with CI experience in fact a lower level of activity and participation in daily
life, work and social activities [4]. Moreover, CI interferes with coping strategies, adherence to
treatments and capability to benefit from rehabilitative strategies [5,6]. A few studies tried to
focus on potential risk factors or protective factors for MS-related CI [3], even if without
strong results. In this respect, especially information on environmental and lifestyle risk factors
would be of help in adopting preventive strategies, identifying subjects at higher risk for CI
and fostering assessment and management strategies.
The objective of this exploratory study is to identify possible risk factors/protective factors




We included MS patients with relapsing–remitting (RR), primary and secondary progressive
MS (PPMS, SPMS) [7] referred to the local MS center in the period from 2014 to 2017. Inclu-
sion criteria were: diagnosis of MS (2010 revisions of the McDonald criteria), age� 18 years,
interval between diagnosis and inclusion into the study� 10 years, no relapses or steroid treat-
ment in the month before the neuropsychological testing, no history of developmental intellec-
tual disability, complicated brain trauma, psychosis and dementing disease other than MS. All
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the patients underwent neuropsychological testing and answered a detailed interview on
hypothesized risk factors at the presence of a caregiver. The study was approved by the Ethics
Committee of the University of Florence, and written informed consent was obtained from the
patients and their caregivers.
Clinical and neuropsychological assessment
Demographic and clinical data were prospectively collected every six months and in occasion
of relapses and stored in an electronic database [8]. Information including disease onset, dis-
ease course, treatments, relapses and disability level assessed on the Expanded Disability Status
Scale (EDSS) [9] was reviewed by the neurologist of the center. A well-trained psychologist
administered the patients the Brief Repeatable Battery of Neuropsychological Tests (BRB) [10]
and Stroop test [11].
The BRB assesses the cognitive domains most frequently impaired in MS and incorporates
tests of verbal memory (Selective Reminding Test [SRT]); visual memory (10/36 Spatial Recall
Test [SPART]); complex attention and information processing speed (Paced Auditory Serial
Addition Test [PASAT]; Symbol Digit Modalities Test [SDMT]); and verbal fluency (Word
List Generation). The Stroop Color and Word Test (SCWT) [11] assesses complex attention
and aspects of executive functioning such as the ability to inhibit cognitive interference. Failure
of a test was defined when the score was below the 5th or above the 95th percentile (1.65 SD), as
appropriate, employing normative Italian values [12]. Patients were classified as having CI
when they failed at least three neuropsychological tests, based on previous studies where using
the same neuropsychological battery we found that less than 5% of healthy controls failed
more than three tests [13–15].
Cognitive reserve was evaluated by the National Adult Reading TEST (NART) [16] and the
Cognitive leisure activity questionnaire [17].
Depression was assessed through the Montgomery-Åsberg Depression Rating Scale
(MADRS) [18] and fatigue was self-assessed by the patients through the Fatigue Severity Scale
(FSS) [19].
The neuropsychological test battery was administered in a single session. Breaks were pro-
vided upon the subject’s request or when fatigue was evident.
A semi-structured interview, developed ad hoc for the study, was administered by the psy-
chologist to each patient in the presence of the caregiver, to investigate previous and current
exposure to hypothesized risk factors. These included cardiovascular risk factors and comor-
bidities, psychiatric disorders, history of brain trauma, hormonal therapies, body mass index
(BMI), diet and lifestyle (type of diet, vitamin D supplementation due to low vitamin levels,
caffeine intake, smoking, alcohol consumption, cannabis and substance abuse, leisure activi-
ties, current and childhood-adolescence physical activity), as well as family history of MS, psy-
chiatric disorders and dementia. Physical activity was assessed on patient report based on the
International Physical Activity Questionnaire (IPAQ) [20] developed as an instrument for
cross-national monitoring of physical activity and inactivity. Results were reported as catego-
ries: 3. high activity levels; 2. moderate activity levels 1. low activity levels. Category 3 on IPAQ
means vigorous intensity activity on at least 3 days achieving a minimum total physical activity
of at least 1500 metabolic equivalent of task (MET) minutes a week or 7 or more days of any
combination of walking, moderate intensity or vigorous intensity activities, achieving a mini-
mum total physical activity of at least 3000 MET minutes a week. Category 2 is defined as three
or more days of vigorous intensity activity and/or walking of at least 30 minutes per day or five
or more days of moderate intensity activity and/or walking of at least 30 minutes per day or
five or more days of any combination of walking, moderate intensity or vigorous intensity
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activities achieving a minimum total physical activity of at least 600 MET minutes a week.
Finally, category 1 of physical activity is represented by patients’ activities that do not meet any
of the abovementioned criteria.
The whole assessment required about 2 hours with an average of 1.15 hours for the test bat-
tery, fatigue and depression assessment, and 45 minutes for the interview.
The interview used in this study is available as supplementary material.
Statistical analysis
Demographic and clinical characteristics were described as frequency (percentage) and
mean ± standard deviation (SD). Group comparisons were assessed through the Pearson’s chi2
Student t and Mann–Whitney U tests when appropriate.
Possible predictors of CI were assessed through a stepwise multivariable logistic model,
including the presence of CI as dependent variable and all the variables that were significant in
the univariate analysis as covariates. Results are expressed as odds ratios (ORs) or estimated
means, and 95% confidence intervals (CIs). P-values less than 0.05 were considered
significant.
Results
All the patients accepted the study procedures. One hundred and fifty MS patients were
included; 45 (30%) were classified as cognitively impaired and 105 (70%) as cognitively pre-
served. The main demographic and clinical characteristics of the study sample are depicted on
Table 1. Compared with cognitively preserved patients, patients with CI were older (p =
0.003), had a higher age at MS onset (p = 0.016), higher EDSS score (p = 0.001), progressive
disease course (p = 0.048) and a lower premorbid IQ score (p = 0.004).
Table 1. Demographic and clinical characteristics of the study sample.





Age, years (mean ± SD) 44.9 ± 11.1 48.9 ± 12.4 43.1 ± 10.1 0.003
Sex (M/F) 47/103 11/34 36/69 0.234
Education, years (mean ± SD) 12.6 ± 3.8 11.8 ± 4.3 12.9 ± 3.5 0.101
Disease duration, years (mean ± SD) 11.2 ± 9.3 11.7 ± 9.8 11.0 ± 9.2 0.690
Age at onset (mean ± SD) 33.6 ± 10.4 37.0 ± 10.9 32.2 ± 9.8 0.016
EDSS median (IQR) 2.0 (1.5–4.0) 3.0 (2.0–5.5) 2.0 (1.0–3.1) 0.001





CP n = 9 (8.6%)
0.048
FSS (mean ± SD) 4.5 ± 1.9 4.9 ± 1.7 4.3 ± 2.0 0.089
Moderate/Severe Depression # (%) 11 (7.3%) 6 (13.3%) 5 (4.8%) 0.065
Relapses in the year prior to inclusion (mean ± SD) 0.3 ± 0.6 0.3 ± 0.6 0.3 ± 0.6 0.680
Mean premorbid IQ score (mean ± SD) 107.1 ± 7.3 104.4 ± 9.3 108.3 ± 5.9 0.004
DMD therapy#
(%)
First-line (IFN-beta,GA,DMF,TRF) 102 (68%) 29 (64,4%) 73 (69,5%) NS
Second-line (NTZ,FNG,AZA,MTX,
RTX)
23 (15,3%) 5 (11,1%) 18 (17,1%) NS
Not treated 25 (16,7%) 11 (24,4%) 14 (13,3%) NS
EDSS: Expanded Disability Status Scale; SD: Standard Deviation; RR: relapsing-remitting; CP: chronic progressive; FSS: Fatigue Severity Scale; MADRS: Montgomery-
Asberg Depression Rating Scale; IQ intelligence quotient; DMD: disease modifying drugs; IFN: interferon; GA: glatiramer acetate; DMF: dimethyl fumarate; TRF:
teriflunomide; NTZ: natalizumab; FNG: fingolimod; AZA: azathioprine; MTX: methotrexate; RTX; rituximab; NS = not significant.
https://doi.org/10.1371/journal.pone.0222929.t001
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As for the profile of cognitive dysfunction, the domains most frequently failed by the
patients were information processing speed (69 subjects, 46%), executive functioning (39,
26%), verbal learning (41, 27%) and visuo-spatial learning (26, 17%). The mean number of
tests failed was 3.01 ± 2.19, the median number 2.
Tables 2 and 3 show the results of the univariate analysis regarding exposure to the hypoth-
esized risk factors. As regard physical activity, we used the IPAQ score to categorize the sub-
jects in 3 classes (low, moderate and high physical activity). Considering physical activity in
childhood and adolescence, two (1,3%) patients didn’t practice any physical activity, while 126
(84%) practiced low level of physical activity, 15 (10%) did moderate and 7 (4,7%) high inten-
sity physical exercise. For the statistical analysis, childhood and adolescence physical activity
was considered as a dichotomized value (yes/no), since the vast majority of the patients (94%,
n = 141) did low-moderate physical activity.
CI was related with lower physical activity in childhood and adolescence (44%, p = 0.008).
Analyzing separately the different IPAQ categories, there was no statistical difference (data not
shown).
In female patients, hormonal therapy resulted to be protective against CI (26,1%,
p = 0.041).
Moreover, a multivariable analysis including only those variables that were significant in
the univariate assessment (p� 0.05) was conducted, and its results reported in Table 4.
In the multivariable analysis, the only significant variable associated with CI were older age (p =
0.004; OR 1.06; 95% CI: 1.02–1.10) and premorbid IQ (p = 0.004; OR 0.93; 95% CI: 0.88–0.98).
For female patients (n = 103), the multivariable analysis was carried out including in the
model also hormonal therapy and confirmed the significant role of age (p = 0.012; OR = 1,06;
95% IC: 1.01–1.12) and premorbid IQ (p = 0.003; OR = 0.89; 95% IC: 0.83–0.96).








4 (8.9%) 4 (3.8%) 0.205
Hypertension
# (%)
6 (13.3%) 15 (14.3%) 0.878
Hypercholesterolemia
# (%)
5 (11.1%) 11 (10.5%) 0.908
Hypertriglyceridemia
# (%)
0 (0%) 8 (7.6%) 0.057
Thyroid disease
# (%)
6 (13.3%) 8 (7.6%) 0.270
Mononucleosis
# (%)
7 (16.7%) 26 (28.9%) 0.131
Family History of MS
# (%)
9 (20%) 23 (21.9%) 0.794
Family History of Psychiatric disorder
# (%)
3 (6.7%) 11 (10.5%) 0.462
Family History of Cognitive impairment
# (%)
6 (13.3%) 19 (18.1%) 0.473
BMI
mean ± SD
24.4 ± 4.9 25.0 ± 4.7 0.490
History of brain trauma # (%) 9 (20%) 13 (12.4%) 0.227
Hypertension was defined as blood pressure values persistently above 140/90 mmHg in different measurements, as defined in the 2018 European Society of Cardiology
Guidelines [21] BMI: Body Mass Index; SD: standard deviation.
https://doi.org/10.1371/journal.pone.0222929.t002
Cognitive impairment in multiple sclerosis: An exploratory analysis of possible risk factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0222929 October 21, 2019 5 / 12
Removing the IQ from the model, CI was associated with higher EDSS (p = 0.030;
OR = 1.25; 95% IC: 1.02–1.53), older age at onset of MS (p = 0.045; OR = 1.04; 95% IC: 1.00–
1.08) and, as a trend, physical activity in childhood and adolescence (p = 0.066; OR = 0.49;
95% IC: 0.23–1.05) (Table 5).
Some factors were analyzed in greater detail. Due to incomplete information, smoking was
considered as a dichotomous variable (YES/NO) instead of number of cigarettes per day/packs
for year, while, for alcohol consumption the mean number of drinks per day was used. More-
over, as for the BMI, the mean value was 24.4 ± 4.90 in cognitively impaired and 25.0 ± 4.70
in preserved patients. A BMI>25 (indicating overweight) was observed in 16 cognitively
impaired (35.5%) and 35 preserved patients (33.3%); a BMI between 18 and 25 (indicating nor-
mal weight) was observed in 18 (40%) cognitively impaired and 49 (46.7%) preserved patients;
finally, a BMI<18 (indicating underweight) was found respectively in 1 (2.2%) and 4 (3.8%)
patients in the two groups. All the above differences were not significant.
While in the univariate analysis previous physical activity was a significant protective factor
and in the multivariable analysis it showed a trend towards significance, current physical activ-
ity was not associated with CI.






Diet: vegetarian/gluten free/lactose free
# (%)
7 (15.6%) 14 (13.3%) 0.719
Vitamin D supplementation
# (%)
20 (44.4%) 52 (49.5%) 0.568
Estroprogestinic therapies�
# (%)
3 (8.8%) 18 (26.1%) 0.041
Caffeine intake
(mean # of coffee per day ± SD)
2.2 ± 1.5 2.5 ± 1.6 0.296
Current smoking
# (%)
16 (35.6%) 39 (37.1%) 0.853
Alcohol
(mean number of drinks per day ± SD)
0.5 ± 0.6 0.5 ± 0.7 0.818
Cannabis
# (%)
1 (2.2%) 4 (3.8%) 0.620
Currently physical activity
# (%)
27 (60%) 48 (45.7%) 0.109
Physical activity in childhood-adolescence
# (%)
20 (44.4%) 71 (67.6%) 0.008
Leisure activities
(mean score ± SD)
11.9 ± 3.9 12.0 ± 3.2 0.797
SD: standard deviation.
� Calculated on 103 women.
https://doi.org/10.1371/journal.pone.0222929.t003
Table 4. Multivariable logistic and linear regression model.
OR 95% CI p
Age, years 1.06 1.02–1.10 0.004
Premorbid IQ 0.93 0.88–0.98 0.004
CI: cognitive impairment. EDSS: Expanded Disability Status Scale. IQ: intelligence quotient. OR: Odds Ratio.
Covariates in the models: age, age at onset, EDSS median, mean premorbid IQ score, physical activity in childhood-
adolescence, disease course, sex.
https://doi.org/10.1371/journal.pone.0222929.t004
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Caffeine intake measured as mean number of coffees per day was comparable between
impaired (2.2 ± 1.5) and preserved (2.5 ± 1.6) patients. One patient in the impaired and four
patients in the preserved group reported use of cannabis, which did not reach the level of sta-
tistical significance.
Finally, considering that other studies have used two-tests failure as a cut-off to identify CI,
we carried out a second multivariable analysis using this criterion to define CI. In this analysis
the role of older age (p = 0.003; OR 1.06; 95% CI: 1.02–1.10) and premorbid IQ (p = 0.011; OR
0.93; 95% CI: 0.88–0.98) was confirmed together with the association of CI with thyroid dis-
eases (p = 0.040; OR 4.52; 95% CI: 1.07–19.09). These were represented by eight cases of hypo-
thyroidism and one case of hyperthyroidism. In these patients, the actual hormonal levels at
the time of the study were however in the normal range.
Discussion
There is limited information about risk factors or protective factors associated with CI in MS.
Among demographic and clinical correlates, aging is clearly associated to a decline of neuro-
psychological performance [22],while conflicting evidence suggests that male sex is a risk fac-
tor for progression of CI [23]. Fatigue, depression and disease duration are weakly correlated
with cognitive capacity [24]. CI is more frequent in patients who are in the progressive phase
of the disease and the profile and severity of cognitive deficits seem to be mostly driven by age
and disability accrual [22]. Several neuroimaging studies have extensively explored MRI corre-
lates of CI in MS, highlighting the relevance of white and grey matter changes and, in particu-
lar, brain volume loss [25].
Our results are in line with previous cross-sectional and longitudinal observations pointing
to the association of CI with older age at onset, aging and disability [22,26]. Early and appro-
priate treatment of the disease with disease modifying drugs can therefore represent a key
strategy to improve both the physical and cognitive outcome of the subject [27].
As for comorbidities, they have been associated with a worse disease outcome [28]. In par-
ticular, cardiovascular risk factors have been associated with brain lesion burden and brain
atrophy [29]. In our sample, using the failure of two tests as the cut-off point to define CI, a
history of thyroid disease was associated with poorer cognitive performance. While further
studies should better analyze this association, thyroid dysfunction represents a relevant, modi-
fiable risk factor that is common in young adults with MS.
Among lifestyle factors, smoking is a well-recognized risk factor for Alzheimer disease and
is related to preclinical changes in the brain, higher risk of cognitive decline, and increased
risk of dementia [30]. In MS smoking is both a susceptibility risk factor for MS and a prognos-
tic factor, associated with disease progression. Moreover, it has been associated with increased
lesion volumes and brain atrophy in multiple sclerosis [31] and CI in one study [32]. Pro-
longed use of inhaled or ingested street cannabis in patients with MS has been associated with
Table 5. Multivariable logistic and linear regression model without IQ.
OR 95% CI p
Age at onset, years 1.04 1.00–1.08 0.045
EDSS 1.25 1.02–1.53 0.030
Physical activity in childhood-adolescence 0.49 0.23–1.05 0.066
CI: cognitive impairment. EDSS: Expanded Disability Status Scale. OR: Odds Ratio.
Covariates in the models: age, age at onset, EDSS median, physical activity in childhood-adolescence, disease course,
sex.
https://doi.org/10.1371/journal.pone.0222929.t005
Cognitive impairment in multiple sclerosis: An exploratory analysis of possible risk factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0222929 October 21, 2019 7 / 12
poor performance on cognitive domains commonly affected in this population [33]. In a
neuropsychological and f-MRI study [34] cannabis use was associated with compromised cere-
bral compensatory mechanisms, already faulty in MS. Lastly, regarding alcohol consumption,
chronic heavy intake is a well-established cause of brain atrophy and dementia [35] although
this association has not been specifically explored in MS.
In our study smoking, cannabis and alcohol intake were not associated with cognitive func-
tioning. In our sample, however, heavy drinkers were not represented. Moreover, we can
hypothesize that, on the one hand, our negative results may be due to relatively small sample
size and, to the other hand, that diagnosis of a chronic disease itself may have led the patient to
modify his/her lifestyle orienting the subject towards healthier inhabits. Finally, we cannot rule
out the possibility of under-report in our patients, particularly for alcohol or cannabis use.
As for potential protective factors, in our study higher cognitive reserve stands out as the
most consistent, potentially modifiable protective factor. In fact, in all the analyses, better
cognitive performance was associated with higher cognitive reserve—expressed as premorbid
IQ—which confirms the findings of other studies [36,37]. In a previous work [37] we found
that the protective role of cognitive reserve mainly applied to the early stages of the disease and
within a hypothetical “threshold” of brain atrophy. However, in our sample of subjects with a
mean age of 45 years and a mean disease duration of 11 years this protective role was still evi-
dent, highlighting the potential of preventive strategies focusing on intellectual enrichment in
this population of patients.
It is noteworthy that in our sample hormonal therapy in female patients resulted to be pro-
tective against CI. This was represented by estroprogestinic oral contraceptives whose exact
dosage and duration of intake were, however, not recorded. A few randomized clinical trials
have reported positive effects of estrogen therapy on cognitive performance [38–42] and the
topic has been extensively reviewed elsewhere [43,44]. In animal studies the estrogens has
been showed to have task-specific effects on cognitive performance and these effects might be
influenced by age and time after loss of ovarian function [45]. One of the proposed mecha-
nisms is that estradiol may enhance performance by increasing cholinergic activity in the hip-
pocampus and cerebral cortex. Furthermore, estradiol effects on hippocampal neurons might
be modulated by cholinergic activity, enabling this hormone to produce lasting changes in cor-
tical connectivity and function [45]. These effects might be moderated by aging, that decreases
cholinergic activity [45].
Hormonal therapy was not retained in our multivariable analysis, and that—in light of the
younger age of the women taking estroprogestinics in our sample—might be due to the more
important influence of aging, rather than the hormonal treatment, on cognitive functions.
In our sample, it is intriguing that physical activity in childhood and adolescence emerged
as a protective factor in the univariate and remained as a trend in the multivariable analysis.
However, in our study we could not document the potential impact of different levels of physi-
cal activity, possibly due to the relatively small sample size and the low proportion of patients
engaged in moderate or high intensity activity.
There is growing evidence deriving from animal studies [46] and human studies in children
and elderly people [47] that physical exercise is connected with greater hippocampal volume,
higher white matter integrity and more efficient white matter activity [47]. Thus, physical
activity may improve cognitive functioning and memory, possibly enhancing hippocampal
function [48]. In MS, physical exercise may be protective against the development of cognitive
dysfunction and exert a synergistic effect together with cognitive rehabilitation in patients with
established CI [49]. However, there is limited information on the potential role of physical
activity in childhood and adolescence. In the general population this has been associated with
reduced morbidity [50], including a decreased risk of MS in a recent study [51]. In the context
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of cognitive functioning, physical exercise early in life might contribute to the building of the
subject cognitive reserve. On the other hand, physical activity could be related to higher socio-
economic status, an acknowledged proxy of cognitive reserve. Based on our findings, further
studies focusing on the pediatric age, using a precise classification of physical exercise in terms
of intensity and duration appear to be highly advisable.
Furthermore, we could not demonstrate any protective role of caffeine intake, that in
healthy adults has been associated with improvement of alertness, vigilance, attention and
reaction time, and, less consistently, memory and higher-order executive functions [52].
Finally, we did not explore the potential impact on cognition of different levels of vitamin
D, whereas one MS study has suggested an association between vitamin D supplementation
and better cognitive performance [53].
Our study has a few limitations, mainly represented by the cross-sectional design and retro-
spective assessment of exposures and potential recall bias. Therefore, the results need to be
confirmed in a larger sample with a more accurate assessment of exposure to hypothesized fac-
tors. Finally, the statistical method used—the stepwise multivariable logistic analysis–although
widely used and appealing because of its simplicity may have some limitations. In fact, it may
be less efficient especially for small studies, where problems such as over-fitting due to data
sparsity and collinearity may arise. Another caveat is the potential bias due to confounding
[54] Causal diagrams utilize assumptions regarding the underlying causal relationships
between relevant variables to perform confounder selection rather than relying on observed
statistical associations. In this respect, the use of multiple models based on multiple potential
direct acyclic graphs (DAGs) could be preferred [55]
Since MS is a multifactorial disease deriving from a complex interplay between genetic and
environmental factors, further investigation is also required on potential genetic susceptibility
to CI [56].
In conclusion, this exploratory study underscores the complexity of physiopathological
mechanisms underlying CI in MS and provides a few clues to further research in this area.
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